|
|||
2015-05-06 08:15:00 CEST 2015-05-06 08:15:58 CEST REGULATED INFORMATION Biotie Therapies - Total number of voting rights and capitalChange in the number of votes relating to Biotie Therapies Corp.'s sharesBIOTIE THERAPIES CORP. Stock Exchange Release 6 May 2015 at 9.15 am Change in the number of votes relating to Biotie Therapies Corp.'s shares Biotie Therapies Corp. ("Biotie" or the "Company") has conveyed Biotie shares held as treasury shares, that were issued on 17 December 2014, pursuant to the Stock Option Plan 2011 (the "Plan") as follows: Shares conveyed Cumulative shares Remaining shares to conveyed since 17 be conveyed December 2014 388,750 2,209,875 237,500 Under the Stock Option Plan 2011, the owners of the stock options may subscribe for a maximum total of 7,401,000 new shares in the Company or existing shares held by the Company, of which a total of 1,844,250 were subscribed for in 2014. A total of 388,750 shares have been subscribed for during the period 23 April 2015 and 5 May 2015 and 388,750 of the treasury shares will be used for these share subscriptions. The subscription price of EUR 0.01 per share has been fully paid by the employee and the EUR 3887.50 funds received will be credited to the Company's reserve for non-restricted equity. Due to share issues already made pursuant to the Stock Option Plan 2011, forfeitures and some of the instruments based on the plan having been left unallocated, a maximum of 2,195,000 shares may still be issued pursuant to the Stock Option Plan 2011. The conveyed shares previously held as treasury shares have not carried any voting rights. The conveyance does not affect the number of registered shares. After the conveyances the changes are as follows: Increase in number Total amount of Number of the Total number of outstanding shares voting rights Company's shares of registered held by the Group shares 388,750 452,990,234 2,977,940 455,968,174 Turku, 6 May 2015 Biotie Therapies Corp. Timo Veromaa, President and CEO For further information, please contact: Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp. tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com www.biotie.com DISTRIBUTION: NASDAQ OMX Helsinki Ltd Main Media [HUG#1918702] |
|||
|